Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259T cells in Synovial Sarcoma.

D'Angelo SP, Melchiori L, Merchant MS, Bernstein DB, Glod J, Kaplan RN, Grupp SA, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite LN, Amado R, Mackall CL.

Cancer Discov. 2018 Jun 11. pii: CD-17-1417. doi: 10.1158/2159-8290.CD-17-1417. [Epub ahead of print]

PMID:
29891538
2.

Prevalence and correlates of recent injecting drug use among gay and bisexual men in Australia: Results from the FLUX study.

Bui H, Zablotska-Manos I, Hammoud M, Jin F, Lea T, Bourne A, Iversen J, Bath N, Grierson J, Degenhardt L, Prestage G, Maher L.

Int J Drug Policy. 2018 May;55:222-230. doi: 10.1016/j.drugpo.2018.01.018. Epub 2018 Feb 9.

PMID:
29429864
3.

Following Lives Undergoing Change (Flux) study: Implementation and baseline prevalence of drug use in an online cohort study of gay and bisexual men in Australia.

Hammoud MA, Jin F, Degenhardt L, Lea T, Maher L, Grierson J, Mackie B, Pastorelli M, Batrouney C, Bath N, Bradley J, Prestage GP.

Int J Drug Policy. 2017 Mar;41:41-50. doi: 10.1016/j.drugpo.2016.11.012. Epub 2017 Jan 9.

PMID:
28081482
4.

Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia.

Fortier E, Alavi M, Bruneau J, Micallef M, Perram J, Sockalingam S, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ, Grebely J; ETHOS Study Group.

J Addict Med. 2017 Jan/Feb;11(1):10-18. doi: 10.1097/ADM.0000000000000261.

PMID:
27775955
5.

Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.

Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, Weltman MD, Day CA, Treloar C, Bath N, Haber PS, Dore GJ; ETHOS Study Group.

Addiction. 2016 Feb;111(2):311-9. doi: 10.1111/add.13197. Epub 2015 Nov 25.

PMID:
26451534
6.

Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.

Keats J, Micallef M, Grebely J, Hazelwood S, Everingham H, Shrestha N, Jones T, Bath N, Treloar C, Dore GJ, Dunlop A; ETHOS Study Group.

Int J Drug Policy. 2015 Oct;26(10):999-1006. doi: 10.1016/j.drugpo.2015.07.006. Epub 2015 Jul 17.

PMID:
26275578
7.

Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study.

Marshall AD, Micallef M, Erratt A, Telenta J, Treloar C, Everingham H, Jones SC, Bath N, How-Chow D, Byrne J, Harvey P, Dunlop A, Jauncey M, Read P, Collie T, Dore GJ, Grebely J.

Int J Drug Policy. 2015 Oct;26(10):984-91. doi: 10.1016/j.drugpo.2015.07.002. Epub 2015 Jul 16.

PMID:
26256938
8.

The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study.

Fortier E, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ, Bruneau J, Grebely J; ETHOS Study Group.

Int J Drug Policy. 2015 Nov;26(11):1094-102. doi: 10.1016/j.drugpo.2015.06.001. Epub 2015 Jun 11.

PMID:
26145482
9.

Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study.

Alavi M, Micallef M, Fortier E, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ, Grebely J; ETHOS Study Group.

J Viral Hepat. 2015 Nov;22(11):914-25. doi: 10.1111/jvh.12415. Epub 2015 May 21.

PMID:
25996567
10.

Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.

Treloar C, Rance J, Bath N, Everingham H, Micallef M, Day C, Hazelwood S, Grebely J, Dore GJ.

Int J Drug Policy. 2015 Oct;26(10):992-8. doi: 10.1016/j.drugpo.2015.01.005. Epub 2015 Jan 24.

PMID:
25697089
11.

How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting.

Treloar C, Rance J; ETHOS Study Group.

Int J Drug Policy. 2014 Sep;25(5):865-70. doi: 10.1016/j.drugpo.2014.01.011. Epub 2014 Jan 26.

PMID:
24559604
12.

Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.

Treloar C, Rance J, Dore GJ, Grebely J; ETHOS Study Group.

J Viral Hepat. 2014 Aug;21(8):560-7. doi: 10.1111/jvh.12183. Epub 2013 Dec 3.

PMID:
24299222
13.

Investigating the balance of reporting maternal and infant outcomes in pregnancy and childbirth Cochrane reviews.

Starrick E, Bath N, Haas DM.

Am J Perinatol. 2014 Sep;31(8):689-94. doi: 10.1055/s-0033-1357266. Epub 2013 Oct 9.

PMID:
24108666
14.

Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection.

Crawford S, Bath N.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S75-9. doi: 10.1093/cid/cit297. Review.

PMID:
23884070
15.

Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.

Alavi M, Grebely J, Micallef M, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ; Enhancing Treatment for Hepatitis C in Opioid Substitution Settings (ETHOS) Study Group.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S62-9. doi: 10.1093/cid/cit305.

PMID:
23884068
16.

Injecting drug use among gay and bisexual men in Sydney: prevalence and associations with sexual risk practices and HIV and hepatitis C infection.

Lea T, Mao L, Bath N, Prestage G, Zablotska I, de Wit J, Holt M.

AIDS Behav. 2013 May;17(4):1344-51. doi: 10.1007/s10461-013-0409-0.

PMID:
23321949
17.

Poor uptake of community based sexually transmissible infection testing at an inner city needle and syringe program.

Martin L, Crawford S, Knight V, Bath N, McNulty A.

Sex Health. 2013 May;10(2):183-4. doi: 10.1071/SH12078.

PMID:
23158773
18.

Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment.

Madden A, Lea T, Bath N, Winstock AR.

Drug Alcohol Rev. 2008 Nov;27(6):671-8. doi: 10.1080/09595230801935706.

PMID:
19378450
19.

Consumers' and providers' perspectives about consumer participation in drug treatment services: is there support to do more? What are the obstacles?

Bryant J, Saxton M, Madden A, Bath N, Robinson S.

Drug Alcohol Rev. 2008 Mar;27(2):138-44. doi: 10.1080/09595230701829405.

PMID:
18264873
20.

Consumer participation in the planning and delivery of drug treatment services: the current arrangements.

Bryant J, Saxton M, Madden A, Bath N, Robinson S.

Drug Alcohol Rev. 2008 Mar;27(2):130-7. doi: 10.1080/09595230701829397.

PMID:
18264872

Supplemental Content

Loading ...
Support Center